Solubility and Improved Patient Outcomes
As poorly soluble drug products continue to pose a significant challenge in the pharmaceutical industry, solubility remains a critical factor in improving patient outcomes. The solubility of an active pharmaceutical ingredient (API) influences the absorption and bioavailability of pharmaceutical compounds, thus directly influencing whether patients reap the full therapeutic benefits of a drug product. Poorly soluble APIs typically require advanced formulation strategies to enhance their stability. This ensures that the drug is dissolving efficiently, reaching the optimum therapeutic level in the bloodstream to trigger a medicinal effect.
The Challenges of Solubility
Modern drug molecules are becoming increasing complex; there is a shift towards more potent and targeted therapies as well as the focus on oral delivery of challenging molecules. With approximately 70-80% of small molecule drug candidates classified with low solubility, pharmaceutical companies require advanced pharmaceutical development methods to accelerate timelines and deliver effective, high-quality treatments to patients.
Addressing Poor Solubility
Tackling poor solubility in APIs is one of the most critical steps in early drug development as it directly affects a molecules’ bioavailability and overall therapeutic success. To overcome this challenge, pharmaceutical companies and CDMOs must understand how the API behaves in biological environments: Physicochemical Testing: Physicochemical tests provide data on how an API behaves once consumed by the patient. By taking into consideration stability, dissolution rates and bulk density, analysing the physical characteristics of the molecule can help pharmaceutical companies and CDMOs to devise an effective drug development programme.
For instance, CDMOs like Almac may utilise a range of in vitro and in silico modelling techniques to predict the in vivo behaviour of a compound. Such strategies help scientists identify solubility and dissolution limitations, as well as model API behaviour under physiologically relevant conditions.
Methods for Bioavailability Enhancement
Innovative approaches such as jet milling, micronisation, spray drying, melt extrusion, and the use of cyclodextrins or lipid‑based systems help maintain solubility and thereby enhance API bioavailability. CDMOs like Almac grant access to these innovative solutions and combine scientific insight, advanced technologies and collaborative expertise to overcome solubility barriers.
Excipient Selection and Screening
Choosing the right excipients to add to the API is critical for stability and scalability throughout the product pipeline. At Almac, we screen API across broad panels to identify systems that maximise solubility without compromising safety and quality.
Addressing issues with solubility leads to a greater flexibility in dosage forms, consistent therapeutic outcomes and can accelerate time to market. As such, solubility is critical to delivering safe and effective treatments to patients. By partnering with CDMOs with access to innovative technologies and technical experts, pharmaceutical companies can overcome these solubility barriers and introduce new pharmaceutical treatments to patients quickly, safely and confidently.
